Many nursing home residents are refusing COVID shots this winter, though flu vaccine penetration has remained strong historically.

Vaxcyte (PCVX) announced that the first study participants have been dosed in the second and final stage of the ongoing Phase 2 study of VAX-31 in healthy infants. Advancement to Stage 2 follows a ...

Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...

With this addition, the Sultanate's immunisation programme now includes 12 vaccines to prevent 12 vaccine-preventable diseases. Vaccinations under the programme are provided free of charge at Maternal ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

SAN CARLOS, Calif. - Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company valued at $10.78 billion, has announced the commencement of the final stage of its Phase 2 study for VAX-31, a ...

Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Capvaxive be used to prevent invasive disease ...

Pennsylvania’s school immunization requirements can be found in 28 Pa.CODE CH.23 (school immunization). For more information, visit www.health.pa.gove/topics/programs/immunizations/Pages/School.aspx ...

Uvax Bio, a privately held vaccine developer founded in 2018 as a spin-off from Scripps Research, has appointed chief ...

The U.S. Senate Finance Committee could vote as soon as Tuesday on Robert F. Kennedy Jr.’s controversial nomination to be ...

The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, ...